Triple Negative Breast Cancer Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Triple Negative Breast Cancer pipeline constitutes 165+ key companies continuously working towards developing 170+ Triple Negative Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Triple Negative Breast Cancer Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Triple Negative Breast Cancer Market.

The Triple Negative Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Get a Free Sample PDF Report to know more about Triple Negative Breast Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key takeaways from the Triple Negative Breast Cancer Pipeline Report:
• Companies across the globe are diligently working toward developing novel Triple Negative Breast Cancer treatment therapies with a considerable amount of success over the years.
• Triple Negative Breast Cancer companies working in the treatment market are Sichuan Kelun-Biotech Biopharmaceutical, Akeso Biopharma, ProLynx, ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Jiangsu HengRui Medicine Co., Ltd, Shanghai Henlius Biotech, and others, are developing therapies for the Triple Negative Breast Cancer treatment
• Emerging Triple Negative Breast Cancer therapies in the different phases of clinical trials are- SKB264, AK117, PLX038, mRNA-2752, OTS167PO, PMD-026, X4P-001, BLEX 404, ZEN003694 +Talazoparib, mprime PGG, IPI-549, Trilaciclib, Camrelizumab, HLX10, and others are expected to have a significant impact on the Triple Negative Breast Cancer market in the coming years.
• In February 2026, The U.S. Food and Drug Administration (FDA) granted Priority Review to AstraZeneca's Datroway (datopotamab deruxtecan) following acceptance of its supplemental Biologics License Application (sBLA). The application seeks approval for the first-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not eligible for PD-L1 inhibitor therapy. According to the company, Datroway has the potential to become a new standard of care in this setting, where chemotherapy has traditionally been the only approved option. Priority Review is typically awarded to therapies that may offer meaningful improvements in safety or effectiveness compared to existing treatments.
• In January 2026, CytoDyn (OTCQB: CYDY) announced that an anonymous donor has provided funding to support an Expanded Access Program (EAP) allowing patients with triple-negative breast cancer (TNBC) to receive leronlimab. The company has partnered with WEP Clinical as the CRO and plans to open the program for patient referrals in March 2026, pending FDA approval of a revised protocol. The EAP is designed for patients who have exhausted approved therapies and do not qualify for ongoing clinical trials. The program may also offer insights into PD-L1 induction after leronlimab and potential combination strategies with immune checkpoint inhibitors. Additional details for physicians and patients will be shared on the company's website as the program progresses.
• In September 2025, ProteinQure, a Toronto-based biotech specializing in computational peptide drug discovery, announced the first patient has been dosed in its Phase I clinical trial of PQ203, a novel peptide therapeutic for advanced metastatic solid tumors. This marks the company's first internally developed AI-designed peptide therapy to reach the clinic, just three years after the program's initiation. PQ203 consists of a peptide targeting the Sortilin receptor linked to the cytotoxic agent MMAE. Since the Sortilin receptor is highly expressed in diseased tissue of Triple Negative Breast Cancer (TNBC) patients, PQ203 has shown strong efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (TrodelvyTM), the current standard of care for metastatic TNBC.
• In January 2025, The Novotech Triple Negative Breast Cancer Clinical Trial Report highlighted ongoing drug development across multiple phases, with 78 trials in Phase I, 97 in Phase II, and 12 in Phase III. Key advancements include targeted therapies such as PARP inhibitors, immune checkpoint inhibitors (ICIs), and innovative antibody-drug conjugates (ADCs). Additionally, combination approaches that integrate immunotherapy, chemotherapy, and targeted treatments are improving overall treatment effectiveness.
• In November 2024, A novel treatment strategy developed at Roswell Park Comprehensive Cancer Center demonstrated encouraging results in a Phase 1 clinical trial for patients with triple-negative breast cancer (TNBC), the most aggressive form of the disease.
• In February 2024, Trodelvy (sacituzumab govitecan-hziy) is the first approved antibody-drug conjugate for treating advanced triple-negative breast cancer (TNBC) in adults who have undergone at least two prior treatments for metastatic disease. It is also indicated for pre-treated HR+/HER2- metastatic breast cancer patients and second-line metastatic TNBC patients who have received endocrine-based therapy and at least two other systemic therapies.

Triple Negative Breast Cancer Overview
Triple Negative Breast Cancer (TNBC) is characterized by a tumor that has negative levels of estrogen and progesterone (ER/PR), as determined by immunohistochemistry (IHC), and neither immunohistochemistry (IHC) nor fluorescence in situ hybridization (FISH) has detected overxpression of the HER2 gene.

Explore the latest Triple Negative Breast Cancer pipeline insights 2025, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Triple Negative Breast Cancer Clinical Trials
https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Triple Negative Breast Cancer Drugs Under Different Phases of Clinical Development Include:
• SKB264: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
• AK117: Akeso Biopharma
• PLX038: ProLynx
• mRNA-2752: ModernaTX, Inc.
• OTS167PO: OncoTherapy Science
• PMD-026: Phoenix Molecular Designs
• X4P-001: Abbisko Therapeutics
• BLEX 404: BioLite, Inc.
• ZEN003694 +Talazoparib: Zenith Epigenetics
• mprime PGG: HiberCell, Inc.
• IPI-549: Infinity Pharmaceuticals
• Trilaciclib: G1 Therapeutics, Inc
• Camrelizumab: Jiangsu HengRui Medicine Co., Ltd
• HLX10: Shanghai Henlius Biotech

Triple Negative Breast Cancer Route of Administration
Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Triple Negative Breast Cancer Molecule Type
Triple Negative Breast Cancer Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Triple Negative Breast Cancer Pipeline Therapeutics Assessment
• Triple Negative Breast Cancer Assessment by Product Type
• Triple Negative Breast Cancer By Stage and Product Type
• Triple Negative Breast Cancer Assessment by Route of Administration
• Triple Negative Breast Cancer By Stage and Route of Administration
• Triple Negative Breast Cancer Assessment by Molecule Type
• Triple Negative Breast Cancer by Stage and Molecule Type

DelveInsight's Triple Negative Breast Cancer Report covers around 170+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Triple Negative Breast Cancer product details are provided in the report. Download the Triple Negative Breast Cancer pipeline report to learn more about the emerging Triple Negative Breast Cancer therapies
https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Triple Negative Breast Cancer Therapeutics Market include:
Key companies developing therapies for Triple Negative Breast Cancer are - ModernaTX, Inc, NuGenrex Immuno-Oncology, Pfizer, Jiangsu Alphamab Biopharmaceuticals Co., Ltd., BioLite, Inc., ImmunityBio, Inc., PharmAbcine, Genexine, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Novartis Pharmaceuticals, Klus Pharma, Ayala Pharmaceuticals, Inc, Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, Akeso Biopharma, Chipscreen Biosciences, OncoPep, Inc., Iovance Biotherapeutics, Inc., SynDevRx, Inc., Hoffmann-La Roche, Celcuity, Inc., Amgen, AstraZeneca, NBE-Therapeutics AG, Fusion Pharmaceuticals, Immutep Limited, and others.

Triple Negative Breast Cancer Pipeline Analysis:
The Triple Negative Breast Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Triple Negative Breast Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Triple Negative Breast Cancer Treatment.
• Triple Negative Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Triple Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Triple Negative Breast Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Triple Negative Breast Cancer drugs and therapies
https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Triple Negative Breast Cancer Pipeline Market Drivers
• Increase in the prevalence of Triple Negative Breast Cancer, increasing Research and Development activities are some of the important factors that are fueling the Triple Negative Breast Cancer Market.

Triple Negative Breast Cancer Pipeline Market Barriers
• However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the Triple Negative Breast Cancer Market growth.

Scope of Triple Negative Breast Cancer Pipeline Drug Insight
• Coverage: Global
• Key Triple Negative Breast Cancer Companies: Sichuan Kelun-Biotech Biopharmaceutical, Akeso Biopharma, ProLynx, ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Jiangsu HengRui Medicine Co., Ltd, Shanghai Henlius Biotech, and others
• Key Triple Negative Breast Cancer Therapies: SKB264, AK117, PLX038, mRNA-2752, OTS167PO, PMD-026, X4P-001, BLEX 404, ZEN003694 +Talazoparib, mprime PGG, IPI-549, Trilaciclib, Camrelizumab, HLX10, and others
• Triple Negative Breast Cancer Therapeutic Assessment: Triple Negative Breast Cancer current marketed and Triple Negative Breast Cancer emerging therapies
• Triple Negative Breast Cancer Market Dynamics: Triple Negative Breast Cancer market drivers and Triple Negative Breast Cancer market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.